MedTrace Logo

Individualized Obesity Pharmacotherapy

NCT03374956 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 193

Last updated 2023-07-18

Study results available
· View outcomes & findings →

Summary

The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.

Conditions

Interventions

DRUG

Phentermine-Topiramate

Extended Release at dose of 7.5/46 mg oral daily

DRUG

Liraglutide

dose of 3 mg subcutaneous daily

DRUG

Naltrexone/bupropion

Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)

DRUG

Phentermine

15-37.5 mg oral daily

Sponsors & Collaborators

Principal Investigators

  • Andres J Acosta · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-11
Primary Completion
2022-05-26
Completion
2022-05-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03374956 on ClinicalTrials.gov